Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia.

ABSTRACT:

Background

Hydroxyurea (hydroxycarbamide) promotes the production of foetal haemoglobin (HbF) by reactivating gamma-genes. Evidence has shown clinical benefits of hydroxyurea in people with sickle cell anemia; however, only a few studies have assessed this treatment in people with beta (β)-thalassaemia.

Objectives

The primary objective is to review the efficacy of hydroxyurea in reducing or ameliorating the requirement of blood transfusions in people with transfusion-dependent β-thalassaemia. The second objective is to review the safety of hydroxyurea with regards to severe adverse effects in this population.

Search methods

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register, compiled from electronic database sear

SUBMITTER: Ansari SH 

PROVIDER: S-EPMC6421980 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature